2026-10-05 Product
Natera Launches AFT-70 NAVIGATE Global Phase III Breast Cancer Trial Collaborating with AFT to evaluate Genentech's oral SERD with Signatera-guided CDK4/6 inhibitor therapy
D1 +3.7% · +5d -6.5%
2026-09-23 Regulation Bull
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx Regulatory approval expands Signatera's clinical use in Japan, strengthening its CDx position
D1 +0.0% · +5d +5.8%
› 2 waves of this story2026-09-23 Japan regulatory approval supports treatment decisions with planned 2027 commercial launch, marking international product expansion2026-09-23 Regulatory approval expands Signatera's clinical use in Japan, strengthening its CDx position2026-09-18 Product Bull
Signatera Shows Strong Prognostic Value in Largest Lung Cancer MRD Study Data from >1100 patients strongly predicts recurrence-free and overall survival in resected NSCLC
D1 +0.8% · +5d +11.7%
2026-09-15 Insider selling
Insider selling $18.1M (1) D1 +2.6% · +5d +11.4%
2026-09-14 Insider selling
Insider selling $16.7M (1) D1 +3.9% · +5d +8.4%
2026-09-11 Insider selling
Insider selling $16.4M (1) D1 +0.9% · +5d +12.3%
2026-08-17 → 08-28 Product Bull
Natera and Angiex Collaborate to Evaluate AGX101 Response Using Signatera New partnership phase: using Signatera to track ctDNA in Phase 1 AGX101 trial for deeper treatment insights.
D1 +1.4% · +5d +4.3%
› 3 waves of this story2026-08-17 Latitude used in Kupando Phase 1 to track ctDNA and characterize response to KUP-1012026-08-27 New collaboration expands Signatera's use in monitoring response to nuclear-delivered ADCs2026-08-28 New partnership phase: using Signatera to track ctDNA in Phase 1 AGX101 trial for deeper treatment insights.2026-08-28 Company Bull
Natera and Susan G. Komen Announce National Partnership to Accelerate Breast Cancer Progress Partnership with leading breast cancer organization could expand adoption of Signatera in breast cancer management.
D1 -3.7% · +5d +0.6%
2026-08-15 Capital Bull
Druckenmiller's Q2 13F shows Natera as top holding Top holding at $865M, 3.19M shares, signaling strong conviction
D1 +1.4% · +5d +4.3%
2026-08-07 → 08-08 Earnings Bull
Natera Q2 Loss Narrows, Revenue Beats, Shares Hit All-Time High Shares surge over 20% post-earnings, up 40% YTD, drawing institutional attention
D1 +21.4% · +5d -3.8%
› 2 waves of this story2026-08-07 Q2 rev $752.8M beat est, +37.7% YoY, raises FY guide, shares up after hours2026-08-08 Shares surge over 20% post-earnings, up 40% YTD, drawing institutional attention2026-08-07 → 08-08 Earnings Bull
Natera Q2 Revenue Beats, Raises FY Guide Q2 loss of $0.47/share improves from year-ago $0.74; shares surge over 20% to record high
D1 +21.4% · +5d -3.8%
› 2 waves of this story2026-08-07 Q2 revenue $752.8M beat est., +37.7% YoY, raises FY guidance2026-08-08 Q2 loss of $0.47/share improves from year-ago $0.74; shares surge over 20% to record high2026-08-06 8-K filing
8-K: Item 2.02, Item 9.01 D1 -3.4% · +5d +17.1%
2026-08-06 Earnings
Earnings report Generated approximately $753 million in revenue, up 38% year-over-year; ex true-ups, revenue grew about 40%.
D1 -3.4% · +5d +17.1%
2026-08-05 Product Bull
Natera Submits Signatera to Japan's PMDA for Companion Diagnostic Approval Submission targets muscle-invasive bladder cancer, a key regulatory step for Signatera in Japan
D1 -0.2% · +5d +15.1%
› 2 waves of this story2026-08-05 Application targets muscle-invasive bladder cancer, advancing Signatera's regulatory and commercial footprint in Japan2026-08-05 Submission targets muscle-invasive bladder cancer, a key regulatory step for Signatera in Japan2026-07-25 → 08-05 Capital
Q1 Institutional Moves Continue: Cetera Trims, Druckenmiller Highlights NTRA Cetera cut stake by 9.5%, while Druckenmiller's 18% position draws attention, extending institutional activity narrative
D1 -1.5% · +5d +4.8%
› 3 waves of this story2026-07-25 Two firms increased Natera positions by 44.2% and 1.0% in latest quarter2026-07-25 Two firms disclosed increased Natera positions in recent SEC filings, continuing the recent trend of institutional repositioning.2026-08-05 Cetera cut stake by 9.5%, while Druckenmiller's 18% position draws attention, extending institutional activity narrative2026-07-22 → 07-25 Capital
Institutional Moves: Fifth Third Boosts Stake, CalPERS Reduces NTRA Two funds raised NTRA stakes last quarter, extending the recent institutional repositioning theme without new directional facts.
D1 -1.1% · +5d -3.9%
› 2 waves of this story2026-07-22 Two institutions disclosed opposing position changes in latest 13F filings2026-07-25 Two funds raised NTRA stakes last quarter, extending the recent institutional repositioning theme without new directional facts.2026-07-22 Product Bull
Signatera Publishes MCC Recurrence Prediction Study in JAMA Dermatology Prospective multicenter study shows Signatera outperforms AMERK, adding clinical evidence for the product.
D1 -1.1% · +5d -3.9%
2026-07-22 Capital Bear
Multiple Institutions Adjust Natera Holdings in Q1; CalPERS Cuts Stake by 23.4% Amova reduced by 10.1%, Fifth Third increased by 3373.1%, CalPERS cut by 23.4%, showing institutional divergence.
D1 -1.1% · +5d -3.9%
2026-07-16 Analyst Bull
Druckenmiller's Top Holding Natera Draws Attention Billionaire Druckenmiller's top holding in Natera highlights its investment appeal.
D1 -2.7% · +5d -1.9%
2026-07-16 Regulation Bull
Final MolDx LCD Expands Coverage for Natera's Prospera Portfolio Finalized MolDx LCD expands coverage for Prospera tests, impacting market access.
D1 -2.7% · +5d -1.9%
2026-07-06 8-K filing
8-K: Item 5.02 D1 +1.6% · +5d -3.8%
2026-06-24 Insider selling Bear
Insider selling $12.6M (2) D1 +10.7% · +5d +6.3%
